Posted On: 08/24/2016 7:20:57 PM
Post# of 99221
$NYMX failed breakout / PRs candle recovery $4.45
called 7/23/16 $3.97
Nasdaq CM
Website
Aug 24, 2016 Nymox Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results: Major Reduction in Incidence of Surgery
Aug 24, 2016 Men with enlarged prostates treated with Nymox's fexapotide show profoundly lower incidence of surgeries in long-term crossover study; shares jump 76% Seeking Alpha
Aug 24, 2016 Midday Gainers / Losers
Shares Outstanding 43.81M
Float 26.09M
% Held by Insiders 6.10%
% Held by Institutions 1 2.80%
Shares Short 31.85M
Short Ratio 4.17
Short % of Float 37.15%
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimers disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in Phase III clinical trials for the treatment of enlarged prostate or benign prostatic hyperplasia, as well as is in Phase II clinical trial for low grade localized prostate cancer. The company markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, The Bahamas
called 7/23/16 $3.97
Nasdaq CM
Website
Aug 24, 2016 Nymox Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results: Major Reduction in Incidence of Surgery
Aug 24, 2016 Men with enlarged prostates treated with Nymox's fexapotide show profoundly lower incidence of surgeries in long-term crossover study; shares jump 76% Seeking Alpha
Aug 24, 2016 Midday Gainers / Losers
Shares Outstanding 43.81M
Float 26.09M
% Held by Insiders 6.10%
% Held by Institutions 1 2.80%
Shares Short 31.85M
Short Ratio 4.17
Short % of Float 37.15%
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimers disease. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in Phase III clinical trials for the treatment of enlarged prostate or benign prostatic hyperplasia, as well as is in Phase II clinical trial for low grade localized prostate cancer. The company markets its products in Canada, the United States, Europe, and internationally. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, The Bahamas
(0)
(0)
